74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Bristol-Myers Squibb Co.
Closed
SectorHealthcare
48.68 0.35
Overview
Share price change
24h
Min
46.98
Max
48.84
Income | -1.1B 76M |
|---|---|
Sales | 442M 12B |
P/E Sector Avg | 14.05 57.333 |
EPS | 1.67 |
Dividend yield | 5.04 |
Profit margin | 0.616 |
Employees | 34,100 |
EBITDA | -1.9B 2.6B |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +17.72% upside |
Dividend yield Sector Avg | 5.04% 2.63% |
|---|---|
Next Dividend date | 1 May 2025 |
Next Ex Dividend date | 4 Jul 2025 |
Market Cap | -21B 100B |
|---|---|
Previous open | 48.33 |
Previous close | 48.68 |
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
Bristol-Myers Squibb Co. Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Bristol-Myers Squibb Co. Forecast
Price Target
By TipRanks
17.72% upside
12 Months Forecast
Average 57.13 USD 17.72%
High 70 USD
Low 36 USD
Based on 18 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Bristol-Myers Squibb Co.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
